Previous 10 | Next 10 |
Shares of Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $4.72. So far today approximately 264,000 shares have been exchanged, as compared to an average 30-day volume of 79,000 shares. Potential upside of 9.3% exists for Metacrine Inc., based on a current level of $4.7...
Shares of Metacrine Inc. (NASDAQ:MTCR) traded today at $4.78, breaking its 52-week low. Approximately 264,000 shares have changed hands today, as compared to an average 30-day volume of 79,000 shares. In the past 52 weeks, shares of Metacrine Inc. have traded between the current low of $...
Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $4.75. Approximately 264,000 shares have changed hands today, as compared to an average 30-day volume of 79,000 shares. Metacrine Inc. (NASDAQ:MTCR) has potential upside of 7.1% based on a current price of $4.82 and analys...
Shares of Metacrine Inc. (NASDAQ:MTCR) traded today at $5.23, breaking its 52-week low. So far today approximately 264,000 shares have been exchanged, as compared to an average 30-day volume of 45,000 shares. In the past 52 weeks, Metacrine Inc. share prices are bracketed by a current lo...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s...
Metacrine (MTCR): Q4 net loss of $10.82MCash, cash equivalents and short-term investments of $96.2MPress Release For further details see: Metacrine reports Q4 results
The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14. Lock-up periods will be expiring for 15 companies. For further details see: U.S. IPO Week Ahead: The Spri...
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that final results from the company&...
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conferen...
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been trea...
News, Short Squeeze, Breakout and More Instantly...
A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there...
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information reg...
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progre...